Welcome to our dedicated page for Turbogen Ltd. SEC filings (Ticker: TRBG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Turbogen Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Turbogen Ltd.'s regulatory disclosures and financial reporting.
Turbogen Ltd. (TRBG) disclosed the initial insider holdings of Dan Katz, Vice President of Manufacturing. He beneficially owns 37,157 ordinary shares, including time‑based restricted share units that convert into ordinary shares as they vest. These holdings combine directly owned shares with several RSU grants made between 2023 and 2026.
Katz also holds multiple employee stock options to acquire additional ordinary shares, with exercise prices ranging from $1.79 to $6.18 per share and expiration dates between 2031 and 2036. None of these options have been exercised as of late August 2026.
Turbogen Ltd. (TRBG) reported the initial beneficial ownership of director Ari Izhak Natan Even. He holds 30,649 Ordinary shares directly and 6,925,299 Ordinary shares indirectly through Anglo Turbo, Limited Partnership. He also holds a share option to acquire 397,215 Ordinary shares at an exercise price of $0.10 per share, expiring on November 26, 2032. As of August 25, 2026, 198,607 of these options are vested and none have been exercised.
Turbogen Ltd. (TRBG) reported the initial equity holdings of director and Chief Strategic & BD Officer Dov Friedman. As of August 28, 2026, he holds options to acquire 397,215 ordinary shares at an exercise price of $0.10 per share, expiring on November 26, 2032. These options were granted on November 26, 2025; 50% vested on that grant date and the remaining 50% vest on August 31, 2026, and as of August 25, 2026, 198,607 options are fully vested with none exercised.
Friedman also holds 37,944 ordinary shares directly and has 6,925,299 ordinary shares reported as held indirectly through Anglo Turbo, Limited Partnership. Anglo Turbo is controlled by Anglo Energy Micro Turbine Ltd., whose controlling persons are Friedman and Itzhak Natan Even Ari. The option exercise price was originally set at NIS 0.30 per share and converted for reporting purposes using an exchange rate of NIS 2.994 to USD $1.00 as of August 24, 2026.
Turbogen Ltd. (TRBG) announced that its ordinary shares have been approved for listing on the Nasdaq Capital Market. Trading on Nasdaq begins on August 31, 2026 at market open under the ticker symbol “TRBG”. Turbogen will also maintain its existing listing on the Tel Aviv Stock Exchange under the symbol “TURB.” Company leadership states that the Nasdaq listing is expected to expand its global reach, increase visibility among investors and business partners, and improve liquidity in its shares.
Turbogen Ltd. (TRBG) reports the initial beneficial ownership of Chief Operating Officer Nir Ziv. He directly holds 130,756 ordinary shares, comprising 24,988 shares and RSUs that each convert into one ordinary share. These include RSU grants of 10,384 units from December 31, 2023, 10,384 units from March 30, 2025, and 85,000 units from April 29, 2026, with portions vesting in 6.25% quarterly installments. He also holds employee share options over 201,017 ordinary shares in total, with exercise prices of $3.45, $1.79, $3.39, and $6.18 per share and expirations between 2033 and 2036; some option grants are already fully vested while later grants begin vesting in 2024 and 2027.
Turbogen Ltd. (TRBG) director Gafni Ziv filed an initial ownership report detailing current equity interests. Ziv holds 81,676 Ordinary shares directly. In addition, Ziv holds options over 30,177 Ordinary shares with an exercise price of $2.99 per share, expiring on March 9, 2032. As of August 25, 2026, 20,118 of these options are fully vested and none have been exercised.
Turbogen Ltd. (TRBG) reported the initial holdings of Chief Executive Officer Yaron Gilboa in a Form 3. Gilboa holds 683,906 ordinary shares directly, consisting of ordinary shares and time-vesting restricted share units. He also holds several option grants to acquire additional ordinary shares at exercise prices between $1.29 and $6.18 per share with expirations from 2029 through 2036, all reported as unexercised as of late August 2026.
Turbogen Ltd. (TRBG) reported the initial equity holdings of Chief Financial Officer Hashai Neta Zruya. As of August 25, 2026, she beneficially holds 176,875 ordinary shares, including granted restricted share units, and two option grants over an additional 235,000 ordinary shares at fixed exercise prices.
The 176,875 ordinary shares position consists of 21,875 shares, 70,000 RSUs granted on October 5, 2025 and 85,000 RSUs granted on April 29, 2026. The 2025 RSUs vest 31.25% initially and 6.25% quarterly thereafter, with 21,875 vested and 48,125 unvested as of August 25, 2026. The 2026 RSUs vest in 6.25% quarterly installments, all 85,000 unvested as of that date. Option grants cover 150,000 shares at $5.54 per share expiring October 5, 2035 and 85,000 shares at $6.18 per share expiring April 29, 2036; footnotes state none of these options have been exercised.
Turbogen Ltd. (TRBG) reported that director Shitrit Idan Ben holds options to purchase 30,177 ordinary shares. These options were granted on March 9, 2025, at an exercise price of $2.99 per share and expire on March 9, 2032.
The grant vests in three equal installments of 33.3% beginning March 9, 2025. As of August 25, 2026, 20,118 options are fully vested, and none have been exercised into ordinary shares.
Turbogen Ltd. (TRBG) reported the initial beneficial ownership of securities by director Levy Ethy. Ethy holds share options giving the right to buy 30,177 ordinary shares, granted on March 9, 2025, that vest in three equal installments of 33.3% beginning March 9, 2025. As of August 25, 2026, 20,118 options are fully vested and none have been exercised into ordinary shares. The options carry an exercise price of NIS 8.95 per share, which for this report was converted using an exchange rate of NIS 2.994 to USD $1.00, resulting in an exercise price of $2.99 per share. The options are held directly, relate to 30,177 underlying ordinary shares, become exercisable beginning March 29, 2025, and expire on March 9, 2032.